Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

RxMx

We’re a healthcare company with exceptional technology solutions and longstanding industry experience. Founded by doctors, we’ve built our business on the idea that by automating certain tasks, we can empower HCPs to safely administer specialty medicines without increasing their burden, so they can focus on patients who need their care.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

- PMLiVE

Genetic Digital

We guide healthcare and life sciences organisations through digital transformation. Simplifying the complex world of tech and marketing, we create impactful assets and strategies to drive long-term growth and positive…

View Profile

Creative and design, Digital communications, IT solutions, Marketing consultancies, Medical communications

- PMLiVE

Nmblr

From day-one concept to launch and beyond, Nmblr is the strategy and collaboration platform that partners with biopharma teams.

View Profile

IT solutions

Company Details

RxMx
800 Third Avenue, Suite 2800, New York, New York, 10022, United States
(844) 311 3080
Contact RxMx
Website

 Latest Content from PMHub 

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Press Releases | September 17, 2025 | Innovative Trials

Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

Lucid Strategy Consulting: Empowering Next-Generation Solutions for Life Sciences

Press Releases | September 16, 2025 | Lucid Group Communications Limited

Lucid Group announces the evolution of its consulting division, Lucid Strategy Consulting, setting a new standard for deep-domain, knowledge-led consulting solutions for life sciences. We have brought together two Lucid...

Streamlining European expansion for cell and gene therapies

White Papers and Resources | September 16, 2025 | Uniphar

Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...

Current CGT landscape and future outlook  

White Papers and Resources | September 16, 2025 | Uniphar

What makes CGT unique  Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...

Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals 

White Papers and Resources | September 16, 2025 | Uniphar

This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...

Navigating the complexities of launch preparation for Cell and Gene Therapy

White Papers and Resources | September 16, 2025 | Uniphar

Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...

Virtual Practice, Real Results: The Power of Virtual Patient Simulation

Press Releases | September 15, 2025 | Medscape Education

Simulation has never been more vital in medicine than it is today. As increasing numbers of physicians turn to large language models for clinical answers1, the real differentiator isn’t just...

A New Destination for Oncology Education

Press Releases | September 15, 2025 | Medscape Education

Medscape Oncology is pleased to announce the launch of a groundbreaking new learning space designed to provide education across tumor types and oncology disciplines: PIONEER – PrecIsion Oncology: Navigating EvidEnce...

A Call to Action: Bridging the Adult Immunization Divide

Press Releases | September 12, 2025 | Medscape Education

Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs

Press Releases | September 12, 2025 | Genesis Research Group

On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...